Key Positives From The 3Q Results
9M cumulative revenue reached JPY 16,644M, up 10.2% YoY, marking double-digit top-line growth. Both core segments grew revenue by roughly 10%. Pricing gains on focus products and a recovery in overseas digital certificates drove the increase, so the quality of top-line growth is high. Contract liabilities, a leading indicator of deferred revenue, rose to JPY 3,112M, expanding the recurring revenue base.
- GMO Sign: Three tailwinds supported revenue and profit growth: higher ARPU from the pricing plan revision, development revenue from dedicated environments for large customers, and wider adoption by local governments
- Digital Certificates: New certificate issuance to large overseas customers increased, and overseas revenue is recovering. GMO Trust Login also added large new customers and grew ID counts at existing accounts, while churn stayed low
- Contract Liabilities: JPY 3,112M, +6.5% vs. the prior fiscal year-end. The build-up in deferred revenue improves visibility on revenue from 4Q onward
- 3Q Standalone Operating Income: JPY 412M (our estimate). This was a recovery from JPY 155M in 2Q and also exceeded JPY 390M in the prior-year quarter
- Dividend: Full-year DPS guidance is JPY 74.35, +30.6% YoY. The company allocated the gain on the sale of GMO Digital Lab shares to shareholder returns
Key Concerns From The 3Q Results
Operating income was only JPY 997M, up just 1.4% YoY and well below revenue growth. Cost of goods sold rose 17.2%, outpacing revenue, and gross profit margin fell 2.6pt to 56.9%. Investors need to determine which parts of AI usage fees and ALTUS Advance-related costs are one-off and which are structural.
- Gross Profit Margin: Down 2.6pt YoY to 56.9%. Margin has trended down from the 59% range to the high-50% range since 1Q 2025
- Digital Certificates & Seal Business: Revenue rose 9.9%, but segment profit fell 4.8%. 3Q standalone profit returned to growth, yet weak 1H profit still weighs on the cumulative figure
- Cloud Infrastructure Business: Segment profit fell 9.1% to JPY 149M, and margin was 2.5%. ALTUS Advance launch costs, migration costs and advertising expenses all hit at once
- Net Income: The 57.0% increase was boosted by JPY 440M in extraordinary income from the sale of subsidiary shares. It should be assessed separately from core profit growth
- Full-Year Hurdle: Hitting the full-year operating income plan requires JPY 625M in 4Q standalone (our estimate). That is 27% above the JPY 492M posted in 4Q of the prior year
Focus Areas / Items To Monitor Going Forward
- 4Q Profit Delivery: Can the company generate JPY 625M of operating income in 4Q standalone? The key question is how much of the cost increase will roll off, including one-off items such as ALTUS Advance launch costs and migration costs
- GMO Sign Pricing and Local Government Penetration: We will monitor the impact of the price revision and the spread of local government adoption. A key question is whether area-wide deployments, such as the joint procurement by all 27 municipalities in Yamanashi Prefecture, can be replicated elsewhere
- Monetization of the "AI × Authentication × Infrastructure" Strategy: We will watch when order growth for JOINT Ai Flow by GMO, the SCA with AWS, and the AI agent authentication pilots start to show up in revenue
- What underpins the JPY 625M 4Q standalone operating income target, and what is the quarterly cost outlook?
- What is the breakdown of the 17.2% increase in cost of goods sold? How large are AI usage fees, ALTUS Advance-related costs and migration costs, and how much of each is one-off?
- What drove the cumulative profit decline in the Digital Certificates & Seal Business, and what is the path to segment margin recovery from FY12/2027 onward?
- What is the order size and monetization timeline for GMO AI Connect, and what growth plan justifies the JPY 320M of goodwill?
- How will the company expand CloudCREW using the AWS SCA, and what margin target does it have for the Cloud Infrastructure Business?
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 16,644M | +10.2% |
| Cost of Goods Sold | JPY 7,176M | +17.2% |
| Gross Profit | JPY 9,467M | +5.4% |
| └ Gross Profit Margin | 56.9% | -2.6pt |
| SG&A | JPY 8,470M | +5.9% |
| └ SG&A Ratio | 50.9% | -2.1pt |
| Operating Income | JPY 997M | +1.4% |
| └ Operating Income Margin | 6.0% | -0.5pt |
| Recurring Profit | JPY 1,038M | +8.5% |
| └ FX Loss | JPY 14M | JPY 77M in prior-year period |
| Extraordinary Income (Gain on Sale of Subsidiary Shares) | JPY 440M | Prior-year period: - |
| Quarterly Net Income Attributable to Owners of Parent Company | JPY 1,104M | +57.0% |
| EPS | JPY 96.25 | +57.2% |
| Depreciation and Amortization | JPY 1,387M | +11.3% |
*Margins, SG&A ratio, and YoY changes for EPS, cost of goods sold, SG&A and depreciation are our estimates
- Operating income rose only 1.4%, while recurring profit grew 8.5%. The gap reflects a narrower FX loss, which fell from JPY 77M to JPY 14M
- Net income growth was driven mainly by the JPY 440M gain on the transfer of GMO Digital Lab shares. Extraordinary losses included JPY 17M in business restructuring costs tied to a project review at an overseas subsidiary
- On a 3Q standalone basis, revenue was JPY 5,553M (+7.5% YoY) and operating income was JPY 412M (+5.6% YoY) (our estimates). 3Q standalone gross profit margin was 57.0%, below 60.3% in the prior-year quarter
Performance By Business Segment
By revenue mix, the Digital Certificates & Seal Business accounted for 61.8%, the Cloud Infrastructure Business for 34.4% and the DX Business for 3.8% (gross basis including intersegment sales; our estimates). Both core segments grew revenue by about 10%. However, costs tied to new services and company-wide expense growth pushed their profits lower. The DX Business narrowed its loss as the portfolio restructuring progresses.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Digital Certificates & Seal Business | JPY 10,525M | +9.9% | JPY 839M | -4.8% | 8.0% |
| Cloud Infrastructure Business | JPY 5,867M | +11.5% | JPY 149M | -9.1% | 2.5% |
| DX Business | JPY 652M | -3.6% | JPY -29M | - | -4.5% |
| Adjustments | JPY -400M | - | JPY 37M | - | - |
*Revenue is on a gross basis including intersegment sales. Margins are our estimates
- GMO Sign: New customer acquisition is on track. Higher pricing from the plan revision and development revenue from dedicated environments for large customers lifted both revenue and profit
- GMO Trust Login: Revenue grew on new large-customer wins and higher ID counts at existing customers. Churn remained low
- Digital Certificates (SSL and Client Certificates): Revenue rose on increased new certificate issuance to large overseas customers. Overseas revenue is recovering
- CloudCREW: Sales expanded as corporate DX initiatives and the spread of generative AI drove broader cloud adoption. The Cloud Infrastructure Business grew revenue by 11.5%
- Cloud Infrastructure Business (Profit): Revenue grew, but segment profit fell 9.1%. Launch and migration costs for the new ALTUS Advance cloud platform, plus advertising expenses, weighed on profit
- DX Business: Revenue fell 3.6% after the company sold its GMO Digital Lab shares in July 2026. The segment loss narrowed from JPY 82M to JPY 29M, and resources are being redirected to AI agent-related businesses
- Digital Certificates & Seal Business (Profit): Cumulative segment profit fell 4.8%. 3Q standalone revenue and profit both grew, but not enough to offset the 1H decline
Progress Versus Full-Year Guidance
Revenue progress was 74.7%, ahead of 73.1% a year earlier. Operating income progress was 61.5%, behind 66.6% a year earlier (both our estimates). Net income has already reached 84.1% thanks to extraordinary income. Achieving the full-year plan hinges on delivering JPY 625M of operating income in 4Q standalone.
| Item | Value (3Q Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 16,644M | JPY 22,286M | 74.7% |
| Operating Income | JPY 997M | JPY 1,622M | 61.5% |
| Recurring Profit | JPY 1,038M | JPY 1,589M | 65.3% |
| Net Income Attributable to Owners of Parent Company | JPY 1,104M | JPY 1,312M | 84.1% |
| EPS | JPY 96.25 | JPY 114.38 | 84.1% |
Changes To Guidance
The company did not revise guidance with these results. It had already raised full-year guidance on October 19, 2026 to reflect the JPY 440M gain on the sale of GMO Digital Lab shares. The revised full-year plan calls for revenue of JPY 22,286M (+7.8% YoY), operating income of JPY 1,622M (+10.0% YoY) and net income of JPY 1,312M (+30.5% YoY).
Commentary On Shareholder Returns
- Dividend Increase: The company raised its dividend forecast on October 19, 2026. The year-end dividend is JPY 74.35, up 30.6% from JPY 56.91 in the prior year
- Payout Ratio: The projected payout ratio is 65.0%, in line with 65.0% last year (our estimate). The profit uplift from extraordinary income is also being passed through to dividends
- Treasury Shares: Treasury shares at period-end totaled 223,258, up 11,900 from the prior fiscal year-end
Financial Position
Cash and deposits were JPY 9,215M against interest-bearing debt of JPY 2,599M, so the company remains in a net cash position. The equity ratio rose to 55.6%. Tools, furniture and fixtures rose JPY 348M and goodwill rose JPY 320M. The balance sheet now reflects investment in areas including AI and infrastructure.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Deposits | JPY 9,215M | +3.1% vs. prior fiscal year-end |
| Accounts Receivable and Contract Assets | JPY 2,418M | -16.5% vs. prior fiscal year-end |
| Contract Liabilities | JPY 3,112M | +6.5% vs. prior fiscal year-end |
| Shareholders' Equity | JPY 10,799M | +4.6% vs. prior fiscal year-end |
| Interest-Bearing Debt | JPY 2,599M | Sum of borrowings and lease obligations; -3.6% vs. prior fiscal year-end; our estimate |
| └ Long-Term Borrowings (Incl. Current Portion) | JPY 2,315M | -1.6% vs. prior fiscal year-end |
| └ Lease Obligations | JPY 284M | -17.1% vs. prior fiscal year-end |
| Goodwill | JPY 320M | JPY 0M at prior fiscal year-end; recognized at the time GMO AI Connect was consolidated |
| EBITDA | JPY 2,384M | Operating income + depreciation and amortization; 9M cumulative; +6.9% YoY; our estimate |
| Metric | Value | Notes |
|---|---|---|
| Net Debt/EBITDA | -2.8x | Net cash of JPY 6,616M; based on 9M cumulative EBITDA; our estimate |
| Debt/Equity | 0.24x | 0.26x at prior fiscal year-end; our estimate |
| Interest Coverage Ratio | 32.0x | Operating income ÷ interest expense; 40.4x in prior-year period; our estimate |
| Equity Ratio | 55.6% | +1.1pt vs. prior fiscal year-end; company disclosure |
Disclosures Released Alongside The Earnings Announcement
- 2026/11/12Released supplementary materials for the 3Q results and held a briefing for analysts and institutional investors (FY12/2026 3Q Earnings Presentation Materials)
Major Announcements During The Quarter
- 2026/10/09Signed a Strategic Collaboration Agreement (SCA) with AWS in July 2026. The deal strengthens cloud implementation and operations support, as well as generative AI capabilities, with CloudCREW at the core
- 2026/10/13Yamanashi Prefecture and all 27 of its municipalities jointly procured e-contract services, and every one of them adopted GMO Sign. The deal is an example of area-wide expansion in the local government market, which the earnings release identifies as a focus area
- 2026/10/19Raised full-year guidance to reflect the gain on the transfer of GMO Digital Lab shares. The year-end dividend forecast was also raised to JPY 74.35
- 2026/10/21GMO AI RAG and JOINT Ai Flow by GMO were integrated to offer an end-to-end solution, from referencing internal knowledge to automating business workflows. The integration expands the DX Business's AI connectivity platform
- 2026/10/22GMO Sign launched an "AI Flow Option" that lets users search contracts and send signature requests via AI. The value-added feature combines AI with authentication and aims to lift ARPU
Large-Shareholding Filings / Material Proposals Over The Past Year
None.
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.